Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 78 of 78 drug-target rows in SSL view, for TSG = CDKN1A.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
rosuvastatin CDKN1A HMGCR 2
topotecan CDKN1A TOP1 2
aldoxorubicin, topotecan CDKN1A TOP1 1
amrubicin, topotecan CDKN1A TOP1 1
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, fludarabine phosphate, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy CDKN1A CSF3R 1
anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, methylprednisolone, umbilical cord blood transplantation, radiation therapy CDKN1A CSF3R 1
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine CDKN1A TOP1 1
at-101, topotecan CDKN1A TOP1 1
berzosertib, sacituzumab govitecan CDKN1A TOP1 1
bi 764532, topotecan, single agent chemotherapy CDKN1A TOP1 1
bl-b01d1, topotecan CDKN1A TOP1 1
bnt327 dose level 1 (dl1), bnt327 dose level 2 (dl2), etoposide, carboplatin, paclitaxel, topotecan CDKN1A TOP1 1
carboplatin, irinotecan CDKN1A TOP1 1
cetuximab, filgrastim, fluorouracil, irinotecan hydrochloride, leucovorin calcium CDKN1A CSF3R 1
cetuximab, irinotecan, oxaliplatin, uft CDKN1A TOP1 1
cisplatin, gleevec™, irinotecan CDKN1A TOP1 1
crizotinib CDKN1A MST1R 1
filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy CDKN1A CSF3R 1
filgrastim, busulfan, cyclophosphamide, etoposide, melphalan, autologous-autologous tandem hematopoietic stem cell transplantation, radiation therapy CDKN1A CSF3R 1
filgrastim, carboplatin, cyclophosphamide, paclitaxel, topotecan hydrochloride, peripheral blood stem cell transplantation CDKN1A CSF3R 1
filgrastim, carboplatin, etoposide, ifosfamide, in vitro-treated peripheral blood stem cell transplantation CDKN1A CSF3R 1
filgrastim, carboplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy CDKN1A CSF3R 1
filgrastim, carboplatin, paclitaxel, topotecan hydrochloride CDKN1A CSF3R 1
filgrastim, gemcitabine hydrochloride, vinorelbine tartrate CDKN1A CSF3R 1
filgrastim, paclitaxel, topotecan hydrochloride CDKN1A CSF3R 1
fludarabine phosphate, cyclophosphamide, rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, diphenhydramine, mesna CDKN1A CSF3R 1
gemcitabine, oxaliplatin, dexamethasone, floxuridine (fudr), implanted medical device CDKN1A NOS2 1
imatinib, irinotecan, carboplatin CDKN1A TOP1 1
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide CDKN1A TOP1 1
irinotecan hydrochloride liposome injection, topotecan CDKN1A TOP1 1
irinotecan, carboplatin, bevacizumab CDKN1A TOP1 1
irinotecan, carboplatin, bevacizumab, radiation CDKN1A TOP1 1
irinotecan, carboplatin, bevacizumab, radiation therapy CDKN1A TOP1 1
irinotecan, cisplatin, simvastatin CDKN1A TOP1 1
irinotecan, cisplatin, simvastatin CDKN1A HMGCR 1
irinotecan, docetaxel CDKN1A TOP1 1
irinotecan, lurbinectedin, irinotecan, topotecan, lurbinectedin CDKN1A TOP1 1
laboratory biomarker analysis, pegfilgrastim, pharmacological study, tivantinib, topotecan hydrochloride CDKN1A CSF3R 1
lurbinectedin, irinotecan CDKN1A TOP1 1
lurbinectedin, irinotecan, lurbinectedin, topotecan CDKN1A TOP1 1
ngr-htnf, doxorubicin CDKN1A TOP1 1
nintedanib CDKN1A LCK 1
nintedanib, pembrolizumab CDKN1A LCK 1
pm8002, paclitaxel, topotecan CDKN1A TOP1 1
rubitecan CDKN1A TOP1 1
surufatinib, irinotecan CDKN1A TOP1 1
tarlatamab, lurbinectedin, topotecan, amrubicin CDKN1A TOP1 1
topotecan, belotecan CDKN1A TOP1 1
topotecan, carboplatin CDKN1A TOP1 1
topotecan, sorafenib CDKN1A TOP1 1
atorvastatin CDKN1A HMGCR 2
atorvastatin calcium CDKN1A HMGCR 2
cerivastatin CDKN1A HMGCR 2
cerivastatin sodium CDKN1A HMGCR 2
dasatinib CDKN1A LCK 2
filgrastim CDKN1A CSF3R 2
fluvastatin CDKN1A HMGCR 2
fluvastatin sodium CDKN1A HMGCR 2
irinotecan CDKN1A TOP1 2
irinotecan hydrochloride CDKN1A TOP1 2
lovastatin CDKN1A HMGCR 2
midostaurin CDKN1A PRKCD 2
pazopanib CDKN1A LCK 2
pazopanib hydrochloride CDKN1A LCK 2
pegfilgrastim CDKN1A CSF3R 2
pitavastatin CDKN1A HMGCR 2
pitavastatin calcium CDKN1A HMGCR 2
pitavastatin magnesium CDKN1A HMGCR 2
pitavastatin sodium CDKN1A HMGCR 2
pravastatin CDKN1A HMGCR 2
pravastatin sodium CDKN1A HMGCR 2
rosuvastatin calcium CDKN1A HMGCR 2
sacituzumab govitecan CDKN1A TOP1 2
simvastatin CDKN1A HMGCR 2
topotecan hydrochloride CDKN1A TOP1 2
unnamed compound CDKN1A CSF3R 2
vandetanib CDKN1A LCK 2
trastuzumab deruxtecan CDKN1A TOP1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.